ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial

Protocol No

POLARIS-2022-001-ARGSARC

Staff Member

John Charlson

Phase

III

Summary

This project is being done to assess the effectiveness, safety, and tolerability of an investigational cancer treatment called ADIPEG 20 combined with Gemcitabine and Docetaxel on your smooth muscle cancer called Leiomyosarcoma (LMS).

Objective

A Randomized Phase 3 Trial of ADI-PEG20 in Patients with Leiomeyosarcoma

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL